The Eyes Have It! Why Regeneron Is Hitting A 52-Week High
June 20, 2017 at 10:56 AM EDT
An experimental eye drug from Novartis looks to be a threat to Regeneron's blockbuster drug Eylea. Yet Regeneron's share price is spiking today, and this analyst sees it climbing even higher. Here's why.